Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

BB Biotech stock price, quote, forecast and news

BION.SW
CH0038389992
A0NFN3

Price

42.65 CHF
Today +/-
+0 CHF
Today %
+0 %
P

BB Biotech Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into BB Biotech, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by BB Biotech from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects BB Biotech’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of BB Biotech. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into BB Biotech’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing BB Biotech’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on BB Biotech’s growth potential.

BB Biotech Revenue, EBIT and net profit per share

DateBB Biotech RevenueBB Biotech EBITBB Biotech Net Income
2026e312.22 M CHF191.2 M CHF192.13 M CHF
2025e136.94 M CHF168.96 M CHF214.17 M CHF
2024e126.99 M CHF130.49 M CHF158.22 M CHF
2023530,000 CHF-39.92 M CHF-206.61 M CHF
20221.26 M CHF-43.49 M CHF-357.81 M CHF
2021-343.59 M CHF-403.78 M CHF-404.81 M CHF
2020741.78 M CHF693.11 M CHF691.17 M CHF
2019728.17 M CHF678.67 M CHF677.43 M CHF
20185.78 M CHF-41.64 M CHF-471.34 M CHF
2017730.05 M CHF687.58 M CHF687.5 M CHF
20169.5 M CHF-28.29 M CHF-802.07 M CHF
2015697.95 M CHF654.23 M CHF652.82 M CHF
20141.5 B CHF1.47 B CHF1.47 B CHF
2013950.9 M CHF932 M CHF931.8 M CHF
2012392 M CHF368.6 M CHF367.8 M CHF
2011-47.9 M CHF-65 M CHF-65.1 M CHF
2010-128.1 M CHF-143.3 M CHF-146.3 M CHF
200953.1 M CHF36.3 M CHF36.6 M CHF
200873.8 M CHF48.8 M CHF45.4 M CHF
2007-210.7 M CHF-264.5 M CHF-265.4 M CHF
2006318.3 M CHF298.2 M CHF297.4 M CHF
2005333.3 M CHF319.2 M CHF318 M CHF
2004213.7 M CHF200.8 M CHF202.8 M CHF

BB Biotech Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B CHF)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B CHF)EBIT (B CHF)EBIT MARGIN (%)NET INCOME (B CHF)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
0.150.110.20.241.531.31-0.66-1.530.190.210.330.32-0.210.070.05-0.13-0.050.390.951.50.70.010.730.010.730.74-0.34000.130.140.31
--27.6380.0020.71541.42-14.74-150.19133.69-112.659.7956.34-4.50-166.04-134.76-27.40-341.51-63.28-934.04142.3557.79-53.50-98.718,011.11-99.3214,460.001.79-146.29-100.29--7.94129.41
100.0099.0998.4899.5899.8799.31100.15100.0099.48100.00100.0098.43106.6784.9388.68104.69114.8999.2399.8999.93100.0088.8999.8680.0099.7399.87100.29-----
0.150.110.20.241.531.3-0.66-1.530.190.210.330.31-0.220.060.05-0.13-0.050.390.951.50.70.010.7300.730.74-0.340-0.01000
0.140.090.160.21.451.13-0.78-1.570.180.20.320.3-0.260.050.04-0.14-0.070.370.931.470.65-0.030.69-0.040.680.69-0.4-0.04-0.040.130.170.19
89.4783.6482.8383.6894.8586.07119.21102.4892.7893.9095.8093.71125.7165.7567.92111.72138.3093.8898.1198.0793.83-311.1194.11-820.0093.1393.52117.49-4,300.00-103.17123.5361.22
0.130.090.170.21.461.12-0.79-1.590.180.20.320.3-0.270.050.04-0.15-0.070.370.931.470.65-0.80.69-0.470.680.69-0.4-0.36-0.210.160.210.19
--32.0982.4222.29620.20-23.32-170.56101.14-111.2512.8557.43-6.60-189.23-116.98-20.00-505.56-55.48-664.62153.6857.89-55.65-223.01-185.66-168.56-243.742.07-158.47-11.63-42.30-176.7035.44-10.28
11.99.611.9114.3131.8137.2131.1129.8125.5120.4119.1106.488.582.77965.858.65756.6555.8755.2755.3555.455.455.3955.3655.0154.85000
--------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The BB Biotech Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the BB Biotech is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M CHF)RECEIVABLES (M CHF)OTHER REC. (M CHF)INVENTORIES (M CHF)OTHER CURRENT LIAB. (M CHF)CURRENT ASSETS (M CHF)TANGIBLE ASSETS (M CHF)LONG-T. INVEST. (M CHF)LONG-T. REC. (M CHF)INTANGIBLE ASSETS (M CHF)GOODWILL (M CHF)OTHER NON-CURRENT ASSETS (M CHF)NON-CURRENT ASSETS (M CHF)TOTAL ASSETS (M CHF)LIABILITIESCOMMON STOCK (M CHF)ADDITIONAL PAID-IN CAPITAL (M CHF)RETAINED EARNINGS (M CHF)OTHER EQUITY (M CHF)UNREAL. GAINS/LOSSES (M CHF)EQUITY (M CHF)LIABILITIES (M CHF)PROVISIONS (M CHF)OTHER SHORT-TERM LIAB. (M CHF)SHORT-TERM DEBTS (M CHF)LONG-TERM DEBT PORTION (M CHF)SHORT-TERM REC. (M CHF)LONG-T. LIAB. (M CHF)DEFERRED TAXES (M CHF)OTHER LIAB. (M CHF)LONG-T. LIABILITIES (M CHF)DEBT (M CHF)TOTAL CAPITAL (M CHF)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of BB Biotech provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand BB Biotech's financial health and stability.

Assets

BB Biotech's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that BB Biotech must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of BB Biotech after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into BB Biotech's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M CHF)DEPRECIATION (M CHF)DEFERRED TAXES (M CHF)CHANGES IN WORKING CAPITAL (M CHF)NON-CASH ITEM (M CHF)PAID INTEREST (M CHF)PAID TAXES (M CHF)NET CASH FLOW FROM OPERATING ACTIVITIES (M CHF)CAPITAL EXPENDITURES (M CHF)CASH FLOW FROM INVESTING ACTIVITIES (M CHF)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M CHF)INTEREST INCOME AND EXPENSES (M CHF)NET DEBT CHANGE (M CHF)NET CHANGE IN EQUITY (M CHF)CASH FLOW FROM FINANCING ACTIVITIES (M CHF)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M CHF)TOTAL DIVIDENDS PAID (M CHF)NET CHANGE IN CASH FLOW (M CHF)FREE CASH FLOW (M CHF)SHARE-BASED COMPENSATION (M CHF)
19951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
000000000000000000000000000-3570
00000000000000000000000000000
00000000000000000000000000000
-4-22-32-35-24-241-212-116-18-178-25-16-76-16-10-8-6-254-20-34-28-34-40-45-46-59-44-35
000000000000000000000000003105880
00000000000000000000000000000
00000000000000000000000000000
-55-28-57-147197-672239-74-172107-6-19201509167-2316913411712152115263107215262-94231218
00000000000000000000000000000
230-8-10000000000000000000000000
230-8-10000000000000000000000000
00000000000000000000000000000
049-4921-2100013-13016426-19001405-10-45-6013045-11090-35-872928-58
00172480552000029-284-178-2910-75-119-1373-17-38-10000-80-270
04912269-36531294-18-80-2731-201-504-1375-161-147-92-157-39-126-262-93-205-28491-233-220
0000-15-21294-31-40197-3-7-106000000-10-1-100-1-5
000000000-62-57-44-44-16-29-59-470-51-79-130-160-152-182-168-188-199-212-156
-821433-187392-575710-48-345314-157276527210-3518414713710799132298159269285-39274252
-55.1-28.9-57.8-147.1197.7-672239-74.9-172.2107.3-6.1-19.8201509.4167.8-23.4169.5134.7117.1121.6552.58115.4263.47107.79215.02262.45-94.79231.13218.28
00000000000000000000000000000

BB Biotech stock margins

The BB Biotech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BB Biotech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BB Biotech.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the BB Biotech's sales revenue. A higher gross margin percentage indicates that the BB Biotech retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the BB Biotech's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the BB Biotech's total revenue generated. When comparing the revenue margin year over year, investors can gauge the BB Biotech's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the BB Biotech. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the BB Biotech's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

BB Biotech Margin History

BB Biotech Gross marginBB Biotech Profit marginBB Biotech EBIT marginBB Biotech Profit margin
2026e-994.72 %61.24 %61.54 %
2025e-994.72 %123.38 %156.39 %
2024e-994.72 %102.76 %124.59 %
2023-994.72 %-7,531.13 %-38,982.46 %
2022-36.88 %-3,448.53 %-28,375.26 %
2021100.29 %117.52 %117.82 %
202099.88 %93.44 %93.18 %
201999.83 %93.2 %93.03 %
201881.2 %-720.75 %-8,158.96 %
201799.93 %94.18 %94.17 %
201688.57 %-297.88 %-8,446.35 %
201599.97 %93.74 %93.53 %
201499.96 %98.05 %98.05 %
201399.89 %98.01 %97.99 %
201299.31 %94.03 %93.83 %
2011112.94 %135.7 %135.91 %
2010104.68 %111.87 %114.21 %
200989.45 %68.36 %68.93 %
200884.55 %66.12 %61.52 %
2007106.45 %125.53 %125.96 %
200698.49 %93.69 %93.43 %
200599.97 %95.77 %95.41 %
2004100 %93.96 %94.9 %

BB Biotech Stock Sales Revenue, EBIT, Earnings per Share

The BB Biotech earnings per share therefore indicates how much revenue BB Biotech has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue BB Biotech earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates BB Biotech's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of BB Biotech’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating BB Biotech's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

BB Biotech Revenue, EBIT and net profit per share

DateBB Biotech Sales per ShareBB Biotech EBIT per shareBB Biotech Earnings per Share
2026e5.64 CHF0 CHF3.47 CHF
2025e2.47 CHF0 CHF3.87 CHF
2024e2.29 CHF0 CHF2.86 CHF
20230.01 CHF-0.73 CHF-3.77 CHF
20220.02 CHF-0.79 CHF-6.5 CHF
2021-6.21 CHF-7.29 CHF-7.31 CHF
202013.39 CHF12.51 CHF12.48 CHF
201913.14 CHF12.25 CHF12.23 CHF
20180.1 CHF-0.75 CHF-8.51 CHF
201713.19 CHF12.42 CHF12.42 CHF
20160.17 CHF-0.51 CHF-14.51 CHF
201512.49 CHF11.71 CHF11.68 CHF
201426.47 CHF25.95 CHF25.95 CHF
201316.68 CHF16.35 CHF16.35 CHF
20126.69 CHF6.29 CHF6.28 CHF
2011-0.73 CHF-0.99 CHF-0.99 CHF
2010-1.62 CHF-1.81 CHF-1.85 CHF
20090.64 CHF0.44 CHF0.44 CHF
20080.83 CHF0.55 CHF0.51 CHF
2007-1.98 CHF-2.49 CHF-2.49 CHF
20062.67 CHF2.5 CHF2.5 CHF
20052.77 CHF2.65 CHF2.64 CHF
20041.7 CHF1.6 CHF1.62 CHF

BB Biotech business model

BB Biotech AG is a Swiss investment company specializing in biotechnology and life sciences. The company was founded in 1993 and has been listed on the SIX Swiss Exchange since 1995. BB Biotech AG primarily invests in publicly traded companies in Europe and North America that are active in the biotechnology and healthcare industry. The business model of BB Biotech AG is based on a combination of active portfolio management and long-term investment strategy. The company invests in stocks of biotechnology and healthcare companies that typically do not yet generate profits but are developing promising products or technologies. BB Biotech AG focuses on high portfolio diversification to minimize risk. BB Biotech AG is divided into three business areas: biotechnology, pharmaceuticals, and medtech. The emphasis is on biotechnology, where the company invests in stocks of well-known biotech companies such as Celgene, Gilead Sciences, Regeneron, and Biogen. In the pharmaceutical sector, BB Biotech AG invests in large pharmaceutical companies like Roche, Novartis, or Pfizer. In the medtech sector, the company invests in companies specializing in the development of medical devices and instruments, such as Intuitive Surgical or Neurocrine Biosciences. BB Biotech AG provides added value to its investors through continuous monitoring of the companies in the portfolio and risk management. The company ensures that investors are always informed about the latest developments in the biotechnology and healthcare industry and regularly publishes reports about the portfolio. The portfolio of BB Biotech AG consists of over 30 different biotech, pharmaceutical, and medtech companies. The main holdings of BB Biotech AG are Celgene, Gilead Sciences, Biogen, Incyte, Vertex Pharmaceuticals, Regeneron, and Neurocrine Biosciences. Celgene is one of the world's leading biotech companies specializing in the development of drugs against cancer and other serious diseases. Gilead Sciences is a biotech company specializing in the research of new therapies for the treatment of infectious diseases such as HIV and hepatitis. Biogen is a biotech company specializing in the treatment of neurological disorders such as multiple sclerosis. Incyte is a biotech company specializing in the development of drugs against cancer and inflammatory diseases. Vertex Pharmaceuticals is a biotech company specializing in the treatment of cystic fibrosis. Regeneron is a biotech company specializing in the development of drugs against eye diseases such as macular degeneration and other serious diseases. Neurocrine Biosciences is a medtech company specializing in the development of drugs against sleep disorders and other neurological diseases. BB Biotech AG is an important player in the market for biotechnology and healthcare investments. Through smart selection of investment targets and systematic risk monitoring, the company has enabled investors to achieve high returns with comparatively low risk. Due to these factors, it is now one of the most important holdings in the biotechnology and healthcare sector. BB Biotech is one of the most popular companies on Eulerpool.com.

BB Biotech SWOT Analysis

Strengths

  • Strong market position with a diversified portfolio of healthcare and biotechnology companies.
  • Experienced and knowledgeable management team with a successful track record in the industry.
  • Access to a wide range of investment opportunities in the healthcare sector.

Weaknesses

  • Vulnerability to changes in regulations and policies affecting the healthcare and biotech industries.
  • Dependency on the performance and success of its portfolio companies.
  • Limited ability to influence the strategic decisions of its portfolio companies.

Opportunities

  • Growing demand for innovative healthcare solutions and advancements in biotechnology.
  • Potential for significant returns on investments in high-growth companies in the healthcare sector.
  • Possibility of strategic partnerships and collaborations in the industry.

Threats

  • Intense competition within the healthcare and biotechnology sectors.
  • Economic downturns and market volatility affecting investor sentiment.
  • Risks associated with clinical trial failures and regulatory challenges.

BB Biotech historical P/E ratio, EBIT, and P/S ratio.

BB Biotech shares outstanding

The number of shares was BB Biotech in 2023 — This indicates how many shares 54.846 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue BB Biotech earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates BB Biotech's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of BB Biotech’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating BB Biotech's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

BB Biotech Stock splits

In BB Biotech's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for BB Biotech.

Eulerpool ESG Scorecard© for the BB Biotech stock

Eulerpool World ESG Rating (EESG©)

51/ 100

🌱 Environment

55

👫 Social

36

🏛️ Governance

61

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

BB Biotech list of shareholders

%
Name
Stocks
Change
Date
1.73 % Hunziker (Erich)957,884012/31/2023
1.63 % Zürcher Kantonalbank (Asset Management)905,290-9,7793/31/2024
1.29 % UBS Asset Management (Switzerland)713,25516,9813/31/2024
1.01 % Credit Suisse Asset Management (Schweiz) AG557,2502,6993/31/2024
0.72 % Credit Suisse Funds AG399,3692,7083/31/2024
0.33 % Union Bancaire Privée182,106-10,10812/31/2023
0.27 % Pictet Asset Management Ltd.151,474-1,01312/31/2023
0.23 % Bank Vontobel AG (Private Banking)126,416012/31/2023
0.22 % BlackRock Advisors (UK) Limited119,4061,5183/31/2024
0.16 % Banque Cantonale Vaudoise89,62315,8472/29/2024
1
2
3
4
5
...
10

BB Biotech Executives and Management Board

Dr. Erich Hunziker67
BB Biotech Independent Chairman of the Board (since 2011)
Compensation 400,138 CHF
Dr. Thomas von Planta62
BB Biotech Independent Director
Compensation 282,047 CHF
Dr. Clive Meanwell66
BB Biotech Independent Vice Chairman of the Board (since 2004)
Compensation 278,750 CHF
Prof. Dr. Mads Thomsen63
BB Biotech Independent Director
Compensation 245,000 CHF
Ms. Laura Hamill59
BB Biotech Independent Director
Compensation 195,000 CHF
1
2
3
4

BB Biotech Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Bellevue Group Stock
Bellevue Group
SupplierCustomer0,360,700,800,580,610,54
1

Most common questions regarding BB Biotech

What values and corporate philosophy does BB Biotech represent?

BB Biotech AG represents strong values and a solid corporate philosophy. As a leading biotech investment company, BB Biotech AG focuses on long-term capital appreciation through investments in the biotechnology industry. They strive to support innovative companies that develop cutting-edge therapies and healthcare solutions. This strategy aligns with their commitment to drive advancements and improvements in the healthcare sector. By investing in emerging biotech companies with significant growth potential, BB Biotech AG aims to generate sustainable returns for its shareholders.

In which countries and regions is BB Biotech primarily present?

BB Biotech AG is primarily present in Switzerland and Germany.

What significant milestones has the company BB Biotech achieved?

BB Biotech AG has achieved significant milestones in its history. Some notable achievements include the successful launch of its investment strategy focused on globally listed biotech companies. The company has also been able to deliver consistent returns to its shareholders, with a strong track record of portfolio performance. BB Biotech AG has established itself as a leader in the biotech sector, with a well-diversified portfolio of investments in innovative companies. The company has also been actively involved in supporting the development of breakthrough therapies and advancements in the biotech industry. Overall, BB Biotech AG's achievements reflect its commitment to supporting the growth and success of the biotech sector.

What is the history and background of the company BB Biotech?

BB Biotech AG is a renowned Swiss investment company specializing in the healthcare sector. Established in 1993, BB Biotech has a rich history of success in generating long-term value for its shareholders. The company primarily focuses on investing in innovative biotech companies that exhibit strong growth potential. BB Biotech benefits from an experienced team of professionals dedicated to thoroughly assessing and selecting promising investment opportunities within the biotech industry. With its extensive expertise and broad network, BB Biotech seeks to capitalize on cutting-edge advancements in the healthcare sector. Throughout its history, BB Biotech has consistently delivered impressive returns for investors, solidifying its position as a leading player in the biotech investment space.

Who are the main competitors of BB Biotech in the market?

Some of the main competitors of BB Biotech AG in the market include Roche Holding AG, Novartis AG, and Johnson & Johnson.

In which industries is BB Biotech primarily active?

BB Biotech AG is primarily active in the biotechnology industry.

What is the business model of BB Biotech?

BB Biotech AG is a biotechnology investment company headquartered in Switzerland. The company primarily focuses on investing in a portfolio of innovative and promising biotechnology companies, with a particular emphasis on companies developing and commercializing breakthrough therapies. BB Biotech AG aims to support and generate long-term value by investing in cutting-edge biotech companies that address unmet medical needs and have strong growth potential. By leveraging their extensive expertise and network within the biotech industry, BB Biotech AG aims to provide investors with an attractive investment opportunity in the rapidly evolving field of biotechnology.

What is the P/E ratio of BB Biotech 2024?

The BB Biotech P/E ratio is 14.78.

What is the P/S ratio of BB Biotech 2024?

The BB Biotech P/S ratio is 18.42.

What is the AlleAktien quality score of BB Biotech?

The AlleAktien quality score for BB Biotech is 2/10.

What is the revenue of BB Biotech 2024?

The expected BB Biotech revenue is 126.99 M CHF.

How high is the profit of BB Biotech 2024?

The expected BB Biotech profit is 158.22 M CHF.

What is the business model of BB Biotech

BB Biotech AG is a Swiss investment company specializing in biotechnology. The company actively invests worldwide in biotechnology companies working on innovative therapies to combat various diseases. Their approach focuses on companies developing medications and therapies based on genomic and protein research. The business model of BB Biotech AG is based on their position as strong and experienced investors in the biotechnology field. They invest in a variety of companies within their portfolio that focus on the development of innovative therapeutic options. The company strives for long-term success by investing in companies that utilize innovative technologies for drug manufacturing. BB Biotech AG is a key player in the global biotech market and a significant investor in this sector. In addition to their investment strategy, BB Biotech AG also offers comprehensive consulting services and expertise in the biotechnology and life sciences field. The company supports biotechnology companies in various stages of development, from research and development to drug approval and marketing. Their portfolio includes companies from various areas of biotechnology and life sciences, including biopharmaceuticals, diagnostics, medical technology, and genomics. Some of the key companies in their portfolio are Biotechnology Innovation Organization, Regeneron Pharmaceuticals, Gilead Sciences, Vertex Pharmaceuticals, and Blueprint Medicines. The company aims to actively manage and optimize their portfolio to provide investors with the highest benefit. Through careful research, analysis, and monitoring of biotechnology markets worldwide, BB Biotech AG is able to identify opportunities and act in a timely manner. Overall, BB Biotech AG offers an innovative business model based on a deep understanding of the biotechnology industry and a comprehensive portfolio of companies utilizing innovative technologies for drug manufacturing. The company provides comprehensive investment and consulting services and is a major player in the global biotech market.

What is the BB Biotech dividend?

BB Biotech pays a dividend of 0 CHF distributed over 1 payouts per year.

How often does BB Biotech pay dividends?

BB Biotech pays out a dividend 1 times a year.

What is the BB Biotech ISIN?

The ISIN of BB Biotech is CH0038389992.

What is the BB Biotech WKN?

The WKN of BB Biotech is A0NFN3.

What is the BB Biotech ticker?

The ticker of BB Biotech is BION.SW.

How much dividend does BB Biotech pay?

Over the past 12 months, BB Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BB Biotech is expected to pay a dividend of 0 CHF.

What is the dividend yield of BB Biotech?

The current dividend yield of BB Biotech is .

When does BB Biotech pay dividends?

BB Biotech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of BB Biotech?

BB Biotech paid dividends every year for the past 0 years.

What is the dividend of BB Biotech?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is BB Biotech located?

BB Biotech is assigned to the '-' sector.

Wann musste ich die Aktien von BB Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of BB Biotech from 7/22/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 7/22/2024.

When did BB Biotech pay the last dividend?

The last dividend was paid out on 7/22/2024.

What was the dividend of BB Biotech in the year 2023?

In the year 2023, BB Biotech distributed 0 CHF as dividends.

In which currency does BB Biotech pay out the dividend?

The dividends of BB Biotech are distributed in CHF.

All fundamentals about BB Biotech

Our stock analysis for BB Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BB Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.